Chief Medical and Development Officer · Crinetics Pharmaceuticals, Inc. (CRNX)

Dana Pizzuti

A named executive officer of Crinetics Pharmaceuticals in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$3,910,331

FY2024: $4,209,728

3rd of 6 named executive officers at Crinetics Pharmaceuticals by FY2025 total.

6 named officers on file for Crinetics Pharmaceuticals, FY2025

See an example →

What this number hides

The filing gives the total. Crinetics Pharmaceuticals’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Free

Get Dana Pizzuti’s full pay file as a PDF — free

More than this page: up to 10 years of Dana’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Dana Pizzuti and every company like it: Velarion Intel, free for 3 days, no card →

Dana Pizzuti compensation by year

Crinetics Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Crinetics Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$529,167$550,833$573,333
Bonus——$0
Stock awards$88,380$1,000,730$1,584,980
Option awards$259,770$2,407,290$1,487,018
Non-equity incentive$221,721$247,875$258,000
Pension and deferred compensation——$0
All other$3,000$3,000$7,000
Total$1,102,038$4,209,728$3,910,331

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Crinetics Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001658247-26-000030, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Crinetics Pharmaceuticals, Inc. filed document, accession 0001658247-26-000030. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

$1.1M
$4.2M
$3.9M
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU43,000$2,001,650—
RSU17,250$802,988—
RSU2,250$104,738—
Option43,125—$16.89
Option51,459—$36.86
Option48,938—$43.51
Option6,563—$19.64

Per the Outstanding Equity Awards at Fiscal Year-End table in Crinetics Pharmaceuticals, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Crinetics Pharmaceuticals’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
R. Scott StruthersPresident, Chief Executive Officer and Director$11,628,959
Tobin SchilkeChief Financial Officer$4,357,893
Dana Pizzuti · this pageChief Medical and Development Officer$3,910,331
Stephen BetzChief Scientific Officer$3,827,148
Jeff KnightChief Operating Officer$3,826,671
Marc WilsonFormer Chief Financial Officer$3,255,392

The full Crinetics Pharmaceuticals compensation record

free company brief

This page is one person within Crinetics Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Crinetics Pharmaceuticals's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Crinetics Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order CRNX

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Dana Pizzuti's compensation dossier